(Q35789016)

10 August 2017

1 reference

title

Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization (English)

1 reference

10 August 2017

Brian D Guth

1

1 reference

10 August 2017

Sabine Germeyer

series ordinal

2

1 reference

10 August 2017

Willi Kolb

series ordinal

3

1 reference

10 August 2017

Michael Markert

series ordinal

4

1 reference

10 August 2017

language of work or name

1 reference

1 May 2004

1 reference

Journal of Pharmacological and Toxicological Methods

10 August 2017

published in

1 reference

10 August 2017

volume

49

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

159-169

1 reference

Inhibition of cardiac potassium currents by pentobarbital

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Safety pharmacology and risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Kinetic modulation of HERG potassium channels by the volatile anesthetic halothane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Screening lead compounds for QT interval prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Statistical analysis of QT interval as a function of changes in RR interval in the conscious dog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

HERG K+ channels: friend and foe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

Drug block of I(kr): model systems and relevance to human arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2004.02.006

10.1016/J.VASCN.2004.02.006

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference